EHang Biomedicine
Exosome isolation platform for diagnostics and regenerative medicine.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY20.0m | Series A | |
| Total Funding | 000k | ||
Carrier Biomed (Suzhou) Biomedical Co., Ltd., also known as EHang Biomedicine, is a biotechnology company located in Suzhou Industrial Park, China. The company's scientific team includes scholars from the International Society for Extracellular Vesicles and experts in neurology and clinical oncology. The founding scientist is Professor Hang Hubert Yin. The CEO is Dr. Zhentao Li, who holds a Ph.D. in Molecular Biology from the University of Melbourne.
The company focuses on exosome technology and has developed an independent exosome isolation platform. Its business is structured around several pipelines that leverage large-scale clinical studies. These include the development of early blood diagnostics for neurodegenerative diseases and various cancers.
In addition to diagnostics, EHang Biomedicine operates a translational platform for exosome regenerative medicine. This division works on the development of stem cell-derived exosomes, raw materials from plant-derived exosomes, and related regenerative and aesthetic products. To support these activities, the company operates a 2,700m² GMP-compliant production workshop for exosomes.
Keywords: exosome technology, biomedicine, diagnostics, regenerative medicine, neurodegenerative diseases, cancer diagnostics, stem cell exosomes, Suzhou, clinical studies, GMP production, biotechnology, exosome isolation, aesthetic products, plant-derived exosomes, translational medicine, life sciences, molecular biology, oncology, neurology, clinical research